Ani Pharmaceuticals (ANIP) Tax Provisions (2012 - 2026)

Ani Pharmaceuticals has disclosed Tax Provisions across 15 years of filings, most recently posting $12.4 million for Q2 2026.

• In Q2 2026, Tax Provisions rose 520.0% year-over-year to $12.4 million; the TTM figure through Jun 2026 stood at $34.3 million (up 859.82% YoY), while the FY2025 annual figure was $17.5 million, up 573.01% from the prior year.
• Tax Provisions came in at $12.4 million for Q2 2026 at Ani Pharmaceuticals, up from $10.7 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $12.4 million in Q2 2026 to a low of -$7.3 million in Q3 2024.
• Average Tax Provisions over 5 years is $1.4 million, with a median of $726000.0 recorded in 2023.
• Year-over-year, Tax Provisions slumped 57900.0% in 2022 and surged 881.82% in 2024.
• Over 5 years, Tax Provisions stood at -$1.5 million in 2022, then soared by 85.84% to -$208000.0 in 2023, then sank by 1575.96% to -$3.5 million in 2024, then surged by 213.43% to $4.0 million in 2025, then surged by 213.61% to $12.4 million in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $12.4 million in Q2 2026, $10.7 million in Q1 2026, and $4.0 million in Q4 2025.